TrimRx vs ShedRx: Complete 2026 Comparison

Introduction

TrimRx and ShedRx both operate as GLP-1-focused telehealth platforms prescribing compounded semaglutide and tirzepatide. They look similar at a glance, which makes the detailed comparison the only way to pick.

This piece works through pricing, medication options, provider model, support quality, and the points where each platform tends to win or lose.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What Does Each Platform Actually Do?

TrimRx is a focused GLP-1 weight loss telehealth platform. It prescribes compounded semaglutide and tirzepatide, ships medication monthly from licensed compounding pharmacies, and provides clinician care through an in-house team. The program is structured around 12 to 24 month treatment timelines.

Quick Answer: Both platforms prescribe compounded semaglutide and tirzepatide as core products

ShedRx operates in the same general space. It prescribes compounded semaglutide and tirzepatide, supports patients through dose titration, and runs a similar monthly-pricing structure.

The category convergence reflects market demand. The American Society of Health-System Pharmacists’ 2024 analyses tracked the rise of telehealth-led compounded GLP-1 prescribing as branded supply hit constraints.

How Do the Medication Options Compare?

Both platforms offer compounded semaglutide and compounded tirzepatide as core products. The molecule is the same active ingredient as Ozempic®, Wegovy®, Mounjaro®, and Zepbound®, prepared by 503A or 503B pharmacies.

Some platforms add adjunct medications like B12, vitamin combinations, or anti-nausea support. Both TrimRx and ShedRx make adjuncts available to varying degrees through clinical decision-making.

The trial data for the underlying molecules is platform-agnostic. STEP 1, SURMOUNT-1, SELECT, FLOW, and the SUSTAIN program all reflect the active ingredients that both platforms dispense.

What Does Pricing Look Like at Each?

TrimRx’s compounded semaglutide programs typically run $200 to $300 monthly. Compounded tirzepatide runs $300 to $400. Pricing is set at the platform level and visible before commitment. The free assessment quiz is the entry point.

ShedRx prices fall in similar ranges depending on dose and specific program. Both platforms publish monthly costs on their respective sites and bill monthly without long-term contracts.

The pricing comparison comes down to specific dose tier and any current promotions. Both target the cash-pay patient who wants predictable monthly cost over a year of treatment.

How Does the Provider Experience Compare?

TrimRx pairs patients with a clinician from its in-house team after the intake review. Communication runs through a patient portal with messaging, refill workflows, and dose adjustment forms. Async-first with synchronous options where state requirements specify.

ShedRx uses a similar telehealth structure with a clinical team handling intakes, prescriptions, and follow-up. Both platforms support async messaging as the primary care channel.

For specific provider availability or response time differences, individual reviews vary. A 2024 JD Power telehealth study found that patient satisfaction tracks closely with provider responsiveness across platforms.

How Does State Licensing Coverage Compare?

Both platforms operate in most US states. State availability shifts as licensing expands. Each platform’s site lists current coverage at intake.

If your state isn’t covered by one platform but is by the other, that’s an immediate tiebreaker. Check both sites’ current state lists before completing an intake.

How Does Shipping Work at Each?

Both platforms ship compounded medication directly to patients in cold-chain packaging. Standard timing is 3 to 7 days after clinical approval, with the first shipment from intake submission typically arriving in 7 to 14 days.

Holiday seasons and weather events affect both. Tracking and customer support response times for shipping issues are review-level details where individual reviews vary.

What About Insurance and Coverage?

Neither platform bills insurance directly. Both operate on cash-pay models for compounded medications. HSA and FSA cards are generally accepted for eligible expenses.

For patients with strong commercial insurance coverage of branded GLP-1s, the compounded route at either platform may be more expensive than a branded prescription with insurance applied at a retail pharmacy. The cash-pay structure is built for uninsured or underinsured patients.

KFF reporting through 2024-2025 documented continued utilization management on commercial GLP-1 coverage for weight loss indications.

Key Takeaway: STEP 1 (Wilding et al. 2021 NEJM) showed 14.9% weight loss with semaglutide; SURMOUNT-1 (Jastreboff et al. 2022 NEJM) showed 20.9% with tirzepatide

How Does Safety and Oversight Compare?

Both platforms use US-licensed clinicians and 503A or 503B compounding pharmacies. 503B outsourcing facilities are inspected by the FDA. 503A pharmacies are regulated at the state board level.

The FDA’s October 2024 removal of semaglutide from its drug shortage list affected the regulatory environment for compounding. Both platforms operate within those constraints, prescribing compounded versions for patients with valid clinical indications.

A 2023 JAMA Network Open analysis (Anderson et al.) showed telehealth GLP-1 prescribing can produce comparable clinical outcomes to in-person care with structured titration and adherence support.

What’s Different About Side Effect Management?

Both platforms support patients through dose titration with side effect coaching. Common GLP-1 side effects include nausea, constipation, fatigue at dose changes, and occasional injection site reactions.

The STEP 1 and SUSTAIN trials documented gastrointestinal effects as the leading adverse event category. Structured dose escalation, dietary counseling, and as-needed dose holds are the standard playbook. Both platforms apply this through their clinical workflows.

Patient-reported tolerance through the portal lets the clinician adjust pace. Reviews suggest both platforms are responsive on this, though individual experiences vary.

Where Does Each Platform Tend to Win?

TrimRx’s strengths include established brand presence, predictable monthly pricing, the free assessment quiz, and program-level continuity. Patients on a 12 to 24 month treatment timeline often find the structured program a fit.

ShedRx’s strengths overlap considerably given the convergent market. Specific tiebreakers come down to state licensing, current pricing offers, and any platform-specific features.

For prospective patients, completing the assessment process at both platforms to compare specific personalized treatment plans is the most concrete way to decide.

What Does the Broader GLP-1 Evidence Base Show?

Beyond platform specifics, the underlying evidence for GLP-1 therapy is substantial. The STEP program (Wilding et al. 2021 NEJM and follow-up trials) established semaglutide 2.4 mg as effective for weight loss with 14.9% mean reduction at 68 weeks. The SURMOUNT program (Jastreboff et al. 2022 NEJM) showed tirzepatide 15 mg achieving 20.9% reduction at 72 weeks.

Cardiovascular outcomes data adds context. SELECT (Lincoff et al. 2023 NEJM) showed a 20% reduction in major adverse cardiovascular events with semaglutide in patients with obesity and preexisting cardiovascular disease. FLOW (Perkovic et al. 2024 NEJM) demonstrated kidney and cardiovascular benefits in chronic kidney disease patients with type 2 diabetes.

The molecule is what drives outcomes. Platform choice affects access, cost, and support, but not the fundamental pharmacology.

How Do Platform-level Outcomes Track Drug-level Evidence?

Patient-reported outcomes on telehealth platforms often track the trial data when adherence holds and doses reach maintenance. A 2023 JAMA Network Open analysis (Anderson et al.) found telehealth GLP-1 prescribing produced clinical outcomes comparable to in-person care under structured titration protocols.

Real-world weight loss commonly varies more than trial-population weight loss because adherence is less controlled. Patients who reach maintenance dose and stay on therapy for 12 or more months tend to approach trial-level outcomes. Patients who drop out during titration see smaller effects.

This pattern holds across platforms. The structural differences between providers affect access and cost more than they affect clinical outcomes when the same molecule is delivered at the same dose.

What Should You Check Before Committing to Either Platform?

Three practical checks before signing up. First, state licensing: confirm the platform you want is licensed in your state. Coverage shifts as licensing expands. Second, current pricing: compare the personalized treatment plan output from each platform’s free assessment quiz. Promotional rates shift over time. Third, your insurance situation: if you have strong commercial coverage of branded GLP-1s, the math may favor a branded prescription with insurance applied at a retail pharmacy over either platform.

The 2024 American Gastroenterological Association obesity pharmacotherapy guideline continues to support GLP-1 receptor agonists as first-line agents for chronic obesity management. The clinical case is established; the choice of access path is where patients differentiate.

Bottom line: State licensing coverage and shipping logistics are where small differences appear

FAQ

Are TrimRx and ShedRx Essentially the Same?

They occupy the same category and prescribe similar compounded GLP-1 products. Specific differences come down to state licensing, exact pricing tier, customer support experience, and individual clinical workflows. The category-level similarity is real.

Do Both Prescribe Compounded Tirzepatide?

Yes, both platforms include compounded tirzepatide as a core product. Specific dose availability depends on clinical review and the compounding pharmacy partnership.

Which Is Cheaper, TrimRx or ShedRx?

Pricing at both platforms typically lands in the $200 to $400 monthly range for compounded GLP-1s. The cheaper option for an individual patient depends on the specific medication, dose, and any current promotions. Check both at intake.

Can I Switch Between Them Mid-treatment?

Yes. Switching telehealth providers for a non-controlled medication doesn’t require formal transfer paperwork. Time the switch to avoid medication gaps, ideally with 7 to 14 days of supply remaining.

Do Either Accept Insurance?

Neither bills insurance directly. Both operate on cash-pay structures for compounded medications. HSA and FSA cards are generally accepted.

Which Has Better State Coverage?

Both operate in most states with some exclusions that shift as licensing expands. Check each platform’s current state list at signup. If only one covers your state, that’s the answer.

How Quickly Does Each Ship the First Shipment?

Both target 7 to 14 days from intake submission to first delivery. Clinical review takes 24 to 48 hours, and the compounding pharmacy ships within 3 to 7 days after approval.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.